Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meclizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | CNR1 | P21554 | 2/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.98 |
| ▸ | GHSR | Q92847 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclizine SCHEMBL743819 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL2193375 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL743004 | 0.99 | LMNA (0.98) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL204393 | 0.99 | KCNH2 (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL4650 | 0.99 | KCNH2 (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL4649 | 0.99 | KCNH2 (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL755731 | 0.99 | KCNH2 (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL29374995 | 0.99 | KCNH2 (1.00) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL145896 | 0.98 | KCNH2 (0.98) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 | |
| Meclizine SCHEMBL11659258 | 0.96 | KCNH2 (0.95) | LMNAMEN1KMT2ACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4510 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12193913-B2 | Pet care kit | Puppylation Health, LLC (US) | 2025-01-14 | — | — | US | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| CN-118021984-A | Compound external preparation, preparation method and application thereof | 南方医科大学 | 2024-05-14 | — | — | CN | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| CN-114129525-B | Meclozine orally disintegrating tablet and preparation method thereof | 山东齐都药业有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-114681390-A | Meclozine hydrochloride pharmaceutical composition | 南京宁丹新药技术有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114129525-A | Meclozine orally disintegrating tablet and preparation method thereof | 山东齐都药业有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-114053207-A | Sustained-release pharmaceutical composition and preparation method thereof | 常州恒邦药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114053206-A | Medicinal floating preparation and preparation method thereof | 常州恒邦药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| US-20220008184-A1 | PET CARE KIT | Puppylation Health, LLC (US) | 2022-01-13 | — | — | US | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| US-5053396-A | For treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide | BLASS DAVID H (GB) | 1991-10-01 | — | — | US | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4654209-A | NITROGLYCERINE PLUS STEROID, ANTIHISTAMINE, ANALGESIC, ANTIMICROBIAL | EUROCELTIQUE, S.A. (LU) | 1987-03-31 | — | — | US | claimed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |